Financial Performance - The company's operating revenue for Q1 2025 was ¥73,703,893.55, representing a 28.84% increase compared to ¥57,206,084.70 in the same period last year[5] - Net profit attributable to shareholders reached ¥24,162,307.00, a significant increase of 61.68% from ¥14,944,754.94 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥22,924,937.92, marking an 89.89% increase from ¥12,072,555.57 in the previous year[5] - Basic earnings per share rose to ¥0.37, up 60.87% from ¥0.23 in the same period last year[5] - The diluted earnings per share increased to ¥0.36, reflecting a 56.52% rise from ¥0.23 year-on-year[5] - Total operating revenue for the first quarter reached ¥73,703,893.55, an increase of 29% compared to ¥57,206,084.70 in the previous year[22] - Total operating costs amounted to ¥48,479,325.85, up from ¥43,035,696.85, reflecting a rise of approximately 12%[22] - Net profit for the period was ¥24,162,307.00, representing a significant increase of 62% from ¥14,944,754.94 in the same quarter last year[23] - Basic earnings per share increased to ¥0.37 from ¥0.23, indicating a growth of 61% year-over-year[24] Cash Flow and Assets - The net cash flow from operating activities was ¥29,204,747.03, an 83.88% increase compared to ¥15,882,465.09 in the previous year[5] - The company reported a decrease in cash and cash equivalents to ¥38,367,077.66 from ¥57,454,182.63, indicating a decline of approximately 33.5%[16] - The net cash flow from operating activities increased to ¥29,204,747.03, up from ¥15,882,465.09 in the previous period, representing an increase of 83.5%[29] - Cash inflow from operating activities totaled ¥93,021,906.35, compared to ¥75,466,349.85 in the prior period, reflecting a growth of 23.3%[29] - Cash outflow from operating activities was ¥63,817,159.32, an increase from ¥59,583,884.76, marking a rise of 7.4%[29] - Total assets at the end of the reporting period were ¥815,969,916.38, a 2.09% increase from ¥799,230,324.84 at the end of the previous year[5] - The total assets of the company reached ¥815,969,916.38, compared to ¥799,230,324.84 in the previous period, marking a growth of approximately 2%[20] - The cash and cash equivalents at the end of the period decreased to ¥24,294,568.50 from ¥49,380,615.16, a decline of 50.8%[29] Shareholder Information - The company reported a total of 6,036 common shareholders at the end of the reporting period[11] - The top shareholder, Yuan Yuyu, holds 16.52% of the shares, amounting to 10,987,847 shares, with 8,240,885 shares pledged[11] - The total number of shareholders holding more than 5% of shares and the top 10 shareholders' participation in margin trading is not applicable, indicating stability in shareholder structure[13] - The company has established a unified action agreement between major shareholders, ensuring coordinated decision-making until at least March 31, 2025[13] - The total shares held by major shareholders and their unified action partners amount to 4,547,596 shares, representing a significant portion of the company's equity[13] Investments and Expenses - Research and development expenses rose to ¥7,846,308.01, up 49% from ¥5,277,861.55, highlighting the company's commitment to innovation[23] - The company reported a significant increase in investment income, which rose to ¥1,188,297.56 from ¥850,057.30, an increase of about 40%[23] - Other comprehensive income after tax amounted to ¥51,005.19, contributing positively to the overall financial performance[23] - Cash inflow from investment activities reached ¥164,037,204.41, compared to ¥116,272,060.74, indicating an increase of 41.0%[29] - The net cash flow from investment activities was -¥57,786,572.81, a decline from ¥16,818,004.39 in the previous period[29] - Cash outflow for investment activities was ¥221,823,777.22, significantly higher than ¥99,454,056.35, showing an increase of 123.5%[29] Liabilities and Equity - Total liabilities decreased to ¥88,015,519.85 from ¥99,565,631.88, a reduction of about 12%[20] - The company's total equity increased to ¥727,954,396.53, up from ¥699,664,692.96, reflecting a growth of approximately 4%[20] - Shareholders' equity attributable to the company reached ¥727,954,396.53, up 4.04% from ¥699,664,692.96 at the end of the previous year[5]
迈普医学(301033) - 2025 Q1 - 季度财报